[go: up one dir, main page]

AR091722A1 - Forma cristalina de un derivado de indolinona y su uso - Google Patents

Forma cristalina de un derivado de indolinona y su uso

Info

Publication number
AR091722A1
AR091722A1 ARP130102452A AR091722A1 AR 091722 A1 AR091722 A1 AR 091722A1 AR P130102452 A ARP130102452 A AR P130102452A AR 091722 A1 AR091722 A1 AR 091722A1
Authority
AR
Argentina
Prior art keywords
crystal form
indolinone derivative
crystalline
indolinone
derivative
Prior art date
Application number
Other languages
English (en)
Inventor
Reiser Ulrich
Karl Zahn Stephan
Werthmann Ulrike
Maier Gerd
Michael-Sini Patrizia
Baum Anke
Betzemeier Bodo
Henry Manuel
Herter Rolf
Weber Dirk
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR091722A1 publication Critical patent/AR091722A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Un derivado de indolinona cristalino como se muestra en la descripción, un proceso para su fabricación, y su uso en una terapia frente a la proliferación celular. Reivindicación 1: Etilamida del ácido 3-{3-[1-(4-dimetilaminometil-fenilamino)-1-fenil-met-(Z)-iliden]-2-oxo-2,3-dihidro-1H-indol-6-il}-propinoico caracterizada porque tiene la fórmula (1) o un tautómero o sal farmacéuticamente aceptable de este, en particular en forma cristalina.
ARP130102452 2012-07-11 2013-07-10 Forma cristalina de un derivado de indolinona y su uso AR091722A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12176036 2012-07-11
EP12179105 2012-08-02

Publications (1)

Publication Number Publication Date
AR091722A1 true AR091722A1 (es) 2015-02-25

Family

ID=48747583

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130102452 AR091722A1 (es) 2012-07-11 2013-07-10 Forma cristalina de un derivado de indolinona y su uso

Country Status (5)

Country Link
US (1) US20140018372A1 (es)
AR (1) AR091722A1 (es)
TW (1) TW201416350A (es)
UY (1) UY34902A (es)
WO (1) WO2014009318A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8491927B2 (en) * 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
CN104109159A (zh) 2013-04-17 2014-10-22 杭州普晒医药科技有限公司 苯磺酰胺噻唑化合物的新晶型及其制备方法
EP3148977A4 (en) * 2014-06-02 2018-01-31 Sun Pharmaceutical Industries Ltd Process for the preparation of 4-dimethylaminocrotonic acid
US20190194757A1 (en) * 2014-07-14 2019-06-27 Universitat Zurich Prorektorat Mnw Means and methods for identifying a patient having a BRAF-positive cancer as a non-responder to a BRAF inhibitor as a responder to an MAPK/ERK inhibitor
CN105439879B (zh) * 2014-08-07 2018-08-10 天津法莫西医药科技有限公司 一种反式-4-二甲胺基巴豆酸盐酸盐的制备方法
MX393780B (es) 2017-01-17 2025-03-24 Heparegenix Gmbh Inhibidores de proteina cinasa para promover la regeneracion hepatica o reducir o prevenir la muerte de hepatocitos
US10572185B2 (en) * 2018-06-01 2020-02-25 Western Digital Technologies, Inc. Non-volatile storage system with command replay
CN114981298B (zh) 2019-12-12 2024-08-20 听治疗有限责任公司 用于预防和治疗听力损失的组合物和方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009533480A (ja) 2006-04-24 2009-09-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ３−（アミノメチリデン）２−インドリノン誘導体及びその細胞増殖抑制薬としての使用
EP2167465A1 (en) 2007-06-12 2010-03-31 Boehringer Ingelheim International GmbH Indolinone derivatives and their use in treating disease-states such as cancer
NZ590560A (en) 2008-07-29 2012-12-21 Boehringer Ingelheim Int Indolinone Inhibitors of cell cycle kinases
EP2640860A4 (en) * 2010-11-19 2014-06-04 Univ California COMPOSITIONS AND METHODS FOR DETECTING AND TREATING B-RAF HEMMER RESISTANT MELANOMES
US20130004481A1 (en) * 2011-01-12 2013-01-03 Boehringer Ingelheim International Gmbh Anticancer therapy

Also Published As

Publication number Publication date
WO2014009318A1 (en) 2014-01-16
TW201416350A (zh) 2014-05-01
UY34902A (es) 2014-01-31
US20140018372A1 (en) 2014-01-16

Similar Documents

Publication Publication Date Title
AR091722A1 (es) Forma cristalina de un derivado de indolinona y su uso
EA201401054A1 (ru) N-циклиламиды в качестве нематоцидов
NZ736665A (en) Heterocyclic amides as kinase inhibitors
MY188447A (en) Indazole compounds as fger kinase inhibitor, preparation and use thereof
EA201400333A1 (ru) Бензонитрильные производные в качестве ингибиторов киназ
WO2014028591A3 (en) N-ALKYLATED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
PH12016500676B1 (en) Pyrimidine fgfr4 inhibitors
UY34885A (es) Proteínas de unión anti-mesotelina
TWD157169S (zh) 墨水匣之部分（一）
MX2011007998A (es) Nuevos herbicidas.
UA118666C2 (uk) Похідні піразолу
UA102289C2 (ru) Гербициды, полученные из циклопентадиона
MX2011007932A (es) Herbicidas nuevos.
TWD164994S (zh) 墨水匣之部分（四）
PH12014502294A1 (en) Triazolo compounds as pde10 inhibitors
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
PH12015501038A1 (en) Inhibitors of iap
RU2011135537A (ru) Штамм enterococcus hirae, используемый при производстве кисломолочных продуктов
AR091888A1 (es) Compuestos de urea y su uso como inhibidores de enzimas
TWD158563S (zh) 墨水匣之部分（三）
PH12015501146A1 (en) Hydantoin derivative
MY175703A (en) Tablets with improved acceptance and good storage stability
MX2014005538A (es) 1-piridazinil-hidroxiimino-3-fenil-propanos como agonistas de proteina g-receptor acoplado a acido biliar 1 (gpbar1).
MY182523A (en) Isoxazolidine derivatives
IN2012DN01223A (es)

Legal Events

Date Code Title Description
FB Suspension of granting procedure